Inhibikase Therapeutics Files 8-K
Ticker: IKT · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1750149
Sentiment: neutral
Topics: corporate-governance, filing, shareholder-vote
Related Tickers: IKASE
TL;DR
IKASE filed an 8-K on Jan 6th for Jan 3rd events - amendments, shareholder votes, and financials.
AI Summary
Inhibikase Therapeutics, Inc. filed an 8-K on January 6, 2025, reporting events that occurred on January 3, 2025. The filing indicates amendments to its Articles of Incorporation or Bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Atlanta, Georgia.
Why It Matters
This 8-K filing signals potential corporate governance changes or significant shareholder votes, which could impact the company's strategic direction and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting standard corporate events and does not disclose any immediate financial distress or significant negative news.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- January 3, 2025 (date) — Date of earliest event reported
- January 6, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Atlanta, Georgia (location) — Principal Executive Offices
FAQ
What specific amendments were made to Inhibikase Therapeutics' Articles of Incorporation or Bylaws?
The filing does not specify the exact nature of the amendments to the Articles of Incorporation or Bylaws, only that they were submitted.
What matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but does not detail what those specific matters were.
What financial statements and exhibits are included in this filing?
The filing states that Financial Statements and Exhibits are included, but the specific details of these documents are not provided in the summary text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 3, 2025.
What is the business address and phone number for Inhibikase Therapeutics, Inc.?
The business address is 3350 Riverwood Parkway SE, Suite 1900, Atlanta, Georgia 30339, and the phone number is (678) 392-3419.
Filing Stats: 847 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2025-01-06 06:06:00
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
Filing Documents
- d909904d8k.htm (8-K) — 41KB
- d909904dex31.htm (EX-3.1) — 5KB
- 0001193125-25-001787.txt ( ) — 176KB
- ikt-20250103.xsd (EX-101.SCH) — 3KB
- ikt-20250103_lab.xml (EX-101.LAB) — 19KB
- ikt-20250103_pre.xml (EX-101.PRE) — 12KB
- d909904d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Number Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 6, 2025 INHIBIKASE THERAPEUTICS, INC. By: /s/ Milton H. Werner, Ph.D. Milton H. Werner, Ph.D. President and Chief Executive Officer